Form 4: Larimar Therapeutics Director Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Jonathan S. Leff was granted 55,150 stock options in Larimar Therapeutics, Inc. as part of his board service.
Summary
- Director Jonathan S. Leff received a grant of 55,150 stock options on May 19, 2026.
- The options have an exercise price of $3.33 per share.
- The options are set to expire on May 19, 2036.
- The reporting person disclaims pecuniary interest in these securities, holding them for the benefit of Deerfield Management Company, L.P.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of these options.
Risks
- Vesting is contingent upon continued service on the Board of Directors.
Future Outlook
The options vest on the earlier of May 19, 2027, or the date of the company's next annual meeting of stockholders, subject to continued service.
Management Comments
- The reporting person disclaims beneficial ownership of the securities and holds them for the benefit of Deerfield Management Company, L.P.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize oversight and long-term strategic alignment.
Comparison to Industry Standards
- The grant of stock options to non-executive directors is consistent with standard corporate governance practices for small-cap biotech firms.
- The vesting schedule tied to annual meetings is a common mechanism to ensure director retention.
Related Party Transactions
- The reporting person is a partner in Deerfield Management Company, L.P. and holds these options for their benefit.
Stakeholder Impact
- Minimal impact on shareholders; represents standard director compensation.
Next Steps
- Vesting of options on May 19, 2027, or the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 05/19/2026 | Transaction date of the stock option grant. |
| 05/19/2027 | Vesting date for the granted options (or the date of the next annual meeting). |
| 05/19/2036 | Expiration date of the stock options. |
Keywords
Larimar Therapeutics, LRMR, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.